Drug
Tesofensine clinical trials
Also written NS 2330.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2000
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2003 (3)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2003 | 3 |
| 2006 | 1 |
| 2007 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 12
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 1
Saniona (6) · Boehringer Ingelheim (3) · NeuroSearch A/S (3) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Tesofensine is read from its arms, and is right about nine times in ten.
Testing it · 13
- Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)CompletedPhase 2SanionaNCT03149445Written as Tesofensine/Metoprolol
- 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)CompletedPhase 2SanionaNCT03845075Written as Tesofensine/Metoprolol
- Study of Tesomet With Open-label Extension in Subjects With Prader-Willi SyndromeWithdrawnPhase 2SanionaNCT05198362Written as Tesomet
- Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)WithdrawnPhase 2SanionaNCT05147415Written as Tesomet
- Study to Investigate the Pharmacokinetic ProfileCompletedPhase 1SanionaNCT03286829Written as Tesomet "High dose" in fasted condition
- Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes MellitusCompletedPhase 2SanionaNCT02737891Written as Tesofensine/Metoprolol
- A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)CompletedPhase 2Boehringer IngelheimNCT00148486Written as NS 2330
- A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor FluctuationsCompletedPhase 2Boehringer IngelheimNCT00148512Written as 1. Tesofensine (NS 2330)
- An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's TypeCompletedPhase 2Boehringer IngelheimNCT00153010Written as NS 2330 (Tesofensine)
- Effect of Tesofensine on Weight Reduction in Patients With Obesity.CompletedPhase 2NeuroSearch A/SNCT00394667Written as Tesofensine
- Evaluation of Long Term Safety of Tesofensine in Patients With ObesityCompletedPhase 2NeuroSearch A/SNCT00481104Written as Tesofensine
- Effect of Tesofensine on Energy Balance in Humans.CompletedPhase 1/2NeuroSearch A/SNCT00428415Written as Tesofensine
- Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's DiseaseCompletedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT00006077Written as NS2330
Codes
What other systems call Tesofensine · ClinicalTrials.gg INT005064
- MeSH (NLM) C518479TesofensineOne source NLM
- UNII (FDA) BLH9UKX9V1TESOFENSINEConfirmed FDA, NLM, Wikidata
- Wikidata Q7705544tesofensineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66589TesofensineOne source FDA
- DrugBank DB06156One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C518479 | Tesofensine | One source NLM |
| UNII (FDA) | BLH9UKX9V1 | TESOFENSINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7705544 | tesofensine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66589 | Tesofensine | One source FDA |
| DrugBank | DB06156 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.